Abstract
Abstract
Purpose
Liver function of intensive care patients is routinely monitored by static blood pathology. For specific indications, liver specific cytochrome activity may be measured by the commercially available maximum liver function capacity (LiMAx) test via quantification of the cytochrome P450 1A2 (CYP1A2) dependent C-methacetin metabolism. Sedation with the volatile anesthetic isoflurane was suspected to abrogate the correlation of LiMAx test with global liver function. We hypothesized that isoflurane has a CYP1A2-activity and LiMAx test result decreasing effect.
Methods
In this monocentric, observational clinical study previously liver healthy intensive care patients, scheduled to be changed from propofol to isoflurane sedation, were enrolled. LiMAx testing was done before, during and after termination of isoflurane sedation.
Results
The mean LiMAx value decreased during isoflurane sedation. Septic patients (n = 11) exhibited lower LiMAx values compared to non-septic patients (n = 11) at all time points. LiMAx values decreased with isoflurane from 140 ± 82 to 30 ± 34 µg kg−1 h−1 in the septic group and from 253 ± 92 to 147 ± 131 µg kg−1 h−1 in the non-septic group while laboratory markers did not imply significant hepatic impairment. Lactate increased during isoflurane inhalation without clinical consequence.
Conclusion
Sepsis and isoflurane have independently demonstrated an effect on reducing the hepatic CYP1A2-activity. A network model was constructed that could explain the mechanism through the influence of isoflurane on hypoxia inducible factor (HIF-1α) by upregulation of the hypoxia-inducible pathway and the downregulation of CYP1A2-activity via the ligand-inducible pathway. Thus, the increased anaerobic metabolism may result in lactate accumulation. The influence of isoflurane sedation on the validated correlation of global liver function with CYP1A2-activity measured by LiMAx testing needs to be investigated in more detail.
Publisher
Springer Science and Business Media LLC
Reference42 articles.
1. Horvatits T, Drolz A, Trauner M, Fuhrmann V (2019) Liver injury and failure in critical illness. Hepatology 70:2204–2215
2. Stockmann M, Lock JF, Riecke B, Heyne K, Martus P, Fricke M, Lehmann S, Niehues SM, Schwabe M, Lemke AJ, Neuhaus P (2009) Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg 250:119–125
3. U.S. Food and Drug Administration (2022) Drug development and drug interactions, table of substrates, inhibitors and inducers. In: Editor (ed)^(eds) Book drug development and drug interactions, table of substrates, inhibitors and inducers. City, pp.
4. Kirchner C, Sibai J, Schwier E, Henzler D, Eickmeyer C, Winde G, Köhler T (2019) Dosing of antimycotic treatment in sepsis-induced liver dysfunction by functional liver testing with LiMAx®. Case Rep Crit Care 2019:5362514
5. Kaffarnik MF, Lock JF, Vetter H, Ahmadi N, Lojewski C, Malinowski M, Neuhaus P, Stockmann M (2013) Early diagnosis of sepsis-related hepatic dysfunction and its prognostic impact on survival: a prospective study with the LiMAx test. Crit Care 17:R259